Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance

Cancer Communications

Xiao Xu¹ 

[1] ACEA Biosciences Inc., San Diego, USA

关键词: Epidermal Growth Factor Receptor;    Mutant Epidermal Growth Factor Receptor;    Epidermal Growth Factor Receptor Inhibitor;    Epidermal Growth Factor Receptor Gene;    T790M Mutation;   

DOI  :  10.1186/s40880-015-0029-3

学科分类：肿瘤学

来源: Springer

【 摘 要 】

Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both China and the United States, and the phase 1 trials were initiated in both countries in parallel. In the preclinical studies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys 797 in the ATP-binding pocket, (2) sparing wild-type EGFR, and (3) overcoming T790M-induced resistance. Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clinical trials, and will provide a precision targeted therapy for non-small cell lung cancer patients.

【 授权许可】

CC BY